Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2023 Jan 19;5(3):272–289. doi: 10.1007/s42757-022-0145-7

Prediction of transport, deposition, and resultant immune response of nasal spray vaccine droplets using a CFPD-HCD model in a 6-year-old upper airway geometry to potentially prevent COVID-19

Hamideh Hayati 1, Yu Feng 1,, Xiaole Chen 2, Emily Kolewe 3, Catherine Fromen 3
PMCID: PMC9851113  PMID: 36694695

Abstract

This study focuses on the transport, deposition, and triggered immune response of intranasal vaccine droplets to the angiotensin-converting-enzyme-2-rich region, i.e., the olfactory region (OR), in the nasal cavity of a 6-year-old female to possibly prevent corona virus disease 19 (COVID-19). To investigate how administration strategy can influence nasal vaccine efficiency, a validated multi-scale model, i.e., computational fluid-particle dynamics (CFPD) and host-cell dynamics (HCD) model, was employed. Droplet deposition fraction, size change, residence time, and the area percentage of OR covered by the vaccine droplets, and triggered immune system response were predicted with different spray cone angles, initial droplet velocities, and compositions. Numerical results indicate that droplet initial velocity and composition have negligible influences on the vaccine delivery efficiency to OR. In contrast, the spray cone angle can significantly impact the vaccine delivery efficiency. The triggered immunity was not significantly influenced by the administration investigated in this study due to the low percentage of OR area covered by the droplets. To enhance the effectiveness of the intranasal vaccine to prevent COVID-19 infection, it is necessary to optimize the vaccine formulation and administration strategy so that the vaccine droplets can cover more epithelial cells in OR to minimize the number of available receptors for SARS-CoV-2.

Keywords: computational fluid-particle dynamics (CFPD), host-cell dynamics (HCD), SARS-CoV-2 intranasal vaccine, COVID-19, angiotensin-converting enzyme 2 (ACE-2), 6-year-old female

Acknowledgements

The research was made possible by funding through an award from the Oklahoma Center for the Advancement of Science and Technology (OCAST) (HR19-106). The research is also partially supported by the National Science Foundation (CBET 2120688) and the National Institutes of Health (NIH) Center of Biomedical Research Excellence (COBRE) (P20 GM103648). The use of Ansys software (Ansys Inc., Canonsburg, PA, USA) as part of the Ansys-CBBL academic partnership coordinated by Dr. Thierry Marchal is gratefully acknowledged.

Nomenclature

Ad

droplet surface area (m2)

Cm

correction factor for Fuchs-Knudsen number

cp

specific heat of humid air (J/(kg·K))

cp,d

specific heat of droplet (J/(kg·K))

Dw

water mass diffusivity (m2/s)

dd

droplet diameter (m)

dd,i

droplet initial diameter (m)

dd,f

droplet final diameter (m)

E0

initial number of epithelial cells

FBM

Brownian motion induced force (N)

FD

drag force (N)

FG

gravity (N)

FL

Saffman lift force (N)

g

gravitational acceleration (m/s2)

Hlat

latent heat (J/kg)

Kw

Kelvin effect factor

Kn

Knudsen number

k

turbulence kinetic energy (J/kg)

kc

thermal conductivity (W/(m·K))

kc,t

turbulent thermal conductivity (W/ (m·K))

khc

modified thermal conductivity (W/(m2·K))

kmc

mass transfer coefficient (m/s)

Mw

water molecular weight (kmol/kg)

md

droplet mass (kg)

N

number of fragments between max and min temperature

Nu

Nusselt number

Peq

equilibrium vapor pressure (Pa)

Psat

saturation vapor pressure (Pa)

Pr

Prandtl number

R

gas constant (J/(mol·K))

Red

droplet Reynolds number

rd

droplet radius (m)

Swm

mass source term (kg/(m3·s))

Sc

Schmidt number

Sh

Sherwood number

T

humid airflow temperature (K)

Td

droplet temperature (K)

t

time (s)

u

flow velocity (m/s)

ud

droplet velocity (m/s)

V

breathing velocity (m/s)

Vd,i

droplet initial velocity (m/s)

V¯w

water molar volume (m3/kmol)

yw,surf

water mass fraction at droplet surface

yw,∞

water mass fraction in humid air mixture

Greek symbols

αm

mass accommodation factor

λ

gas mixture mean free path (m)

μ

viscosity of humid air (kg/(m·s))

μt

turbulent viscosity of humid air (kg/(m·s))

μd,surf

viscosity of humid air at droplet surface (kg/(m·s))

ρ

density of humid airflow (kg/m3)

ρw

density of water (kg/m3)

σ

droplet surface tension (N/m)

τ

breathing cycle time (s)

Φexp

experimental values of reported immune response

ΦHCD

computational values obtained for immune response

ω

specific rate of turbulence kinetic energy dissipation (J/(kg·s))

Acronyms

λ-C

λ-carrageenan

ACE-2

angiotensin-converting enzyme 2

CFPD

computational fluid-particle dynamics

COVID-19

corona virus disease 2019

DF

deposition fraction

G

generation

GG

gellan gum

HCD

host-cell dynamics

IgA

immunoglobulin A

IgG

immunoglobulin G

MRI

magnetic resonance imaging

NK

natural killer cells

ODEs

ordinary differential equations

OR

olfactory region

PBS

phosphate-buffered saline

RH

relative humidity

RMSE

root mean squared error

S

spike protein

SARS-CoV-2

severe acute respiratory syndrome corona virus 2

SST

shear stress transport

TB

tracheobronchial

UDFs

user-defined functions

VC

vaccine coverage

VT0

initial viral titer

Author contributions

Conceptualization, H.H., Y.F.; methodology, H.H., Y.F., X.C.; calibration and validation, H.H.; geometry preparation, E.K., C.F., Y.F., H.H.; simulations, H.H.; data curation, H.H.; data analysis, H.H.; writing, original draft, H.H.; writing, review and editing, H.H., E.K., X.C., Y.F.

Declaration of competing interest

The authors have no competing interests to declare that are relevant to the content of this article.

Footnotes

Disclaimer

It is not the intention of authors to provide specific medical advice but rather to provide readers with computational modeling details to better understand the fundamentals of fluid dynamics and host cell dynamics in COVID-19 nasal vaccine development. No in vivo/in vitro studies were conducted. Hence, no specific medical advice will be provided, and the authors urge you to consult with a qualified physician for answers to your personal medical concerns.

References

  1. Asgharian B. A model of deposition of hygroscopic particles in the human lung. Aerosol Science and Technology. 2004;38:938–947. doi: 10.1080/027868290511236. [DOI] [Google Scholar]
  2. Baccam P, Beauchemin C, Macken C A, Hayden F G, Perelson A S. Kinetics of influenza A virus infection in humans. Journal of Virology. 2006;80:7590–7599. doi: 10.1128/JVI.01623-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bird R B, Stewart W E, Lightfoot E N, Spalding D B. Transport phenomena. Journal of Applied Mechanics. 1960;28:317–318. doi: 10.1115/1.3641697. [DOI] [Google Scholar]
  4. Bleier B S, Ramanathan M, Lane A P. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngology-Head and Neck Surgery. 2021;164:305–307. doi: 10.1177/0194599820982633. [DOI] [PubMed] [Google Scholar]
  5. Brechtel F J, Kreidenweis S M. Predicting particle critical supersaturation from hygroscopic growth measurements in the humidified TDMA. Part I: Theory and sensitivity studies. Journal of the Atmospheric Sciences. 2000;57:1854–1871. doi: 10.1175/1520-0469(2000)057<1854:PPCSFH>2.0.CO;2. [DOI] [Google Scholar]
  6. Broday D M, Georgopoulos P G. Growth and deposition of hygroscopic particulate matter in the human lungs. Aerosol Science and Technology. 2001;34:144–159. doi: 10.1080/02786820118725. [DOI] [Google Scholar]
  7. Butler S E, Crowley A R, Natarajan H, Xu S, Weiner J A, Bobak C A, Mattox D E, Lee J, Wieland-Alter W, Connor R I, et al. Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals. Front Immunol. 2021;11:618685. doi: 10.3389/fimmu.2020.618685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Calmet H, Inthavong K, Eguzkitza B, Lehmkuhl O, Houzeaux G, Vázquez M. Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions. PLoS One. 2019;14:e0221330. doi: 10.1371/journal.pone.0221330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chavda V P, Vora L K, Pandya A K, Patravale V B. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discovery Today. 2021;26:2619–2636. doi: 10.1016/j.drudis.2021.07.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chen M, Shen W, Rowan N R, Kulaga H, Hillel A, Ramanathan M, Jr, Lane A P. Elevated ACE-2 expression in the olfactory neuroepithelium: Implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. European Respiratory Journal. 2020;56:2001948. doi: 10.1183/13993003.01948-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chen X, Feng Y, Zhong W, Kleinstreuer C. Numerical investigation of the interaction, transport and deposition of multicomponent droplets in a simple mouth-throat model. Journal of Aerosol Science. 2017;105:108–127. doi: 10.1016/j.jaerosci.2016.12.001. [DOI] [Google Scholar]
  12. El Golli S, Bricard J, Turpin P Y, Treiner C. The evaporation of saline droplets. Journal of Aerosol Science. 1974;5:273–292. doi: 10.1016/0021-8502(74)90062-7. [DOI] [Google Scholar]
  13. Ferron G A, Upadhyay S, Zimmermann R, Karg E. Model of the deposition of aerosol particles in the respiratory tract of the rat. II. Hygroscopic particle deposition. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2013;26:101–119. doi: 10.1089/jamp.2011.0965. [DOI] [PubMed] [Google Scholar]
  14. Flaherty, S. 2021. Children could be dangerous carriers of virus. Available at https://finchannel.com/children-could-be-dangerous-carriers-of-virus/.
  15. Fleming S, Thompson M, Stevens R, Heneghan C, Plüddemann A, Maconochie I, Tarassenko L, Mant D. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: A systematic review of observational studies. Lancet. 2011;377:1011–1018. doi: 10.1016/S0140-6736(10)62226-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Glezen W P. The new nasal spray influenza vaccine. Journal of Pediatric Infectious Diseases. 2001;20:731–732. doi: 10.1097/00006454-200108000-00002. [DOI] [PubMed] [Google Scholar]
  17. Haghnegahdar A, Zhao J, Feng Y. Lung aerosol dynamics of airborne influenza A virus-laden droplets and the resultant immune system responses: An in silico study. Journal of Aerosol Science. 2019;134:34–55. doi: 10.1016/j.jaerosci.2019.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hassan A O, Kafai N M, Dmitriev I P, Fox J M, Smith B K, Harvey I B, Chen R E, Winkler E S, Wessel A W, Case J B, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183:169–184. doi: 10.1016/j.cell.2020.08.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hayati H, Feng Y, Hinsdale M. Inter-species variabilities of droplet transport, size change, and deposition in human and rat respiratory systems: An in silico study. Journal of Aerosol Science. 2021;154:105761. doi: 10.1016/j.jaerosci.2021.105761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hayati H, Soltani Goharrizi A, Salmanzadeh M, Ahmadi G. Numerical modeling of particle motion and deposiiton in turbulent wavy channel flows. Scientia Iranica. 2019;26:2229–2240. [Google Scholar]
  21. Hou Y J, Okuda K, Edwards C E, Martinez D R, Asakura T, Dinnon K H, Kato T, Lee R E, Yount B L, Mascenik T M, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182:429–446. doi: 10.1016/j.cell.2020.05.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Inthavong K, Tian Z F, Li H F, Tu J Y, Yang W, Xue C L, Li C G. A numerical study of spray particle deposition in a human nasal cavity. Aerosol Science and Technology. 2006;40:1034–1045. doi: 10.1080/02786820600924978. [DOI] [Google Scholar]
  23. Inthavong K, Tian Z F, Tu J Y, Yang W, Xue C. Optimising nasal spray parameters for efficient drug delivery using computational fluid dynamics. Computers in Biology and Medicine. 2008;38:713–726. doi: 10.1016/j.compbiomed.2008.03.008. [DOI] [PubMed] [Google Scholar]
  24. Kapadia M, Grullo P E R, Tarabichi M. Comparison of short nozzle and long nozzle spray in sinonasal drug delivery: A cadaveric study. Ear, Nose & Throat Journal. 2019;98:E97–E103. doi: 10.1177/0145561319846830. [DOI] [PubMed] [Google Scholar]
  25. Kiaee M, Wachtel H, Noga M L, Martin A R, Finlay W H. Regional deposition of nasal sprays in adults: A wide ranging computational study. International Journal of Numerical Methods in Biomedical Engineering. 2018;34:e2968. doi: 10.1002/cnm.2968. [DOI] [PubMed] [Google Scholar]
  26. Kitaoka H. A 4D model generator of the human lung. Forma. 2011;26:19–24. doi: 10.1109/EMBC.2013.6609534. [DOI] [PubMed] [Google Scholar]
  27. Kolanjiyil A V, Alfaifi A, Aladwani G, Golshahi L, Longest W. Importance of spray-wall interaction and post-deposition liquid motion in the transport and delivery of pharmaceutical nasal sprays. Pharmaceutics. 2022;14:956. doi: 10.3390/pharmaceutics14050956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Koomen E, Nijman J, Nieuwenstein B, Kappen T. Tidal volume in pediatric ventilation: Do You get what you see? Journal of Clinical Medicine. 2021;11:98. doi: 10.3390/jcm11010098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527. doi: 10.1038/s41586-020-2798-3. [DOI] [PubMed] [Google Scholar]
  30. Kreidenweis S M, Koehler K, DeMott P J, Prenni A J, Carrico C, Ervens B. Water activity and activation diameters from hygroscopicity data — Part I: Theory and application to inorganic salts. Atmospheric Chemistry and Physics. 2005;5:1357–1370. doi: 10.5194/acp-5-1357-2005. [DOI] [Google Scholar]
  31. Lee H Y, Topham D J, Park S Y, Hollenbaugh J, Treanor J, Mosmann T R, Jin X, Ward B M, Miao H, Holden-Wiltse J, et al. Simulation and prediction of the adaptive immune response to influenza A virus infection. Journal of Virology. 2009;83:7151–7165. doi: 10.1128/JVI.00098-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Li, H., Kuga, K., Khoa, N. D., Ito, K. 2021. Effects of initial conditions and parameters on the prediction of SARS-CoV-2 viral load in the upper respiratory tract based on host-cell dynamics. In: Proceedings of International Exchange and Innovation Conference on Engineering & Science Interdisciplinary Graduate School of Engineering Sciences, 7: 155–160.
  33. Long Q X, Liu B Z, Deng H J, Wu G C, Deng K, Chen Y K, Liao P, Qiu J F, Lin Y, Cai X F, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine. 2020;26:845–848. doi: 10.1038/s41591-020-0897-1. [DOI] [PubMed] [Google Scholar]
  34. Longest P W, Xi J. Condensational growth may contribute to the enhanced deposition of cigarette smoke particles in the upper respiratory tract. Aerosol Science and Technology. 2008;42:579–602. doi: 10.1080/02786820802232964. [DOI] [Google Scholar]
  35. Menter F R, Langtry R B, Likki S R, Suzen Y B, Huang P G, Völker S. A correlation-based transition model using local variables—Part I: Model formulation. Journal of Turbomachinery. 2006;128:413. doi: 10.1115/1.2184352. [DOI] [Google Scholar]
  36. Moakes R J A, Davies S P, Stamataki Z, Grover L M. Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis of SARS-COV-2. Advanced Materials. 2021;33:e2008304. doi: 10.1002/adma.202008304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Morrison N A, Talashek T A, Yu H, Raczkowski R. Gellan gum products and methods of manufacture and use thereof. Washington, DC: U.S. Patent and Trademark Office; 2020. [Google Scholar]
  38. Pan Y, Zhang D, Yang P, Poon L L M, Wang Q. Viral load of SARS-CoV-2 in clinical samples. The Lancet Infectious Diseases. 2020;20:411–412. doi: 10.1016/S1473-3099(20)30113-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Parham P. The Immune System. USA: Garland Science; 2014. [Google Scholar]
  40. Pawelek K A, Dor D, Salmeron C, Handel A. Within-host models of high and low pathogenic influenza virus infections: The role of macrophages. PLoS One. 2016;11:e0150568. doi: 10.1371/journal.pone.0150568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Perry R H, Green D W, Maloney J O. Perry’s Chemical Engineers’ Handbook. New York: McGraw-Hill; 1984. [Google Scholar]
  42. Pilicheva B, Boyuklieva R. Can the nasal cavity help tackle COVID-19? Pharmaceutics. 2021;13:1612. doi: 10.3390/pharmaceutics13101612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rygg A, Hindle M, Longest P W. Linking suspension nasal spray drug deposition patterns to pharmacokinetic profiles: A proof-of-concept study using computational fluid dynamics. Journal of Pharmaceutical Sciences. 2016;105:1995–2004. doi: 10.1016/j.xphs.2016.03.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Saffman P G. The lift on a small sphere in a slow shear flow. Journal of Fluid Mechanics. 1965;22:385–400. doi: 10.1017/S0022112065000824. [DOI] [Google Scholar]
  45. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nature Medicine. 2020;26:681–687. doi: 10.1038/s41591-020-0868-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Tong X, Dong J, Shang Y, Inthavong K, Tu J. Effects of nasal drug delivery device and its orientation on sprayed particle deposition in a realistic human nasal cavity. Computers in Biology and Medicine. 2016;77:40–48. doi: 10.1016/j.compbiomed.2016.08.002. [DOI] [PubMed] [Google Scholar]
  47. Vaidya N K, Bloomquist A, Perelson A S. Modeling within-host dynamics of SARS-CoV-2 infection: A case study in ferrets. Viruses. 2021;13:1635. doi: 10.3390/v13081635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Whitaker S. Forced convection heat transfer correlations for flow in pipes, past flat plates, single cylinders, single spheres, and for flow in packed beds and tube bundles. AIChE Journal. 1972;18:361–371. doi: 10.1002/aic.690180219. [DOI] [Google Scholar]
  49. Xi J, Lei L R, Zouzas W, April Si X. Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges. MedComm. 2021;2:569–586. doi: 10.1002/mco2.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Zare F, Aalaei E, Zare F, Faramarzi M, Kamali R. Targeted drug delivery to the inferior meatus cavity of the nasal airway using a nasal spray device with angled tip. Computer Methods and Programs Biomedicine. 2022;221:106864. doi: 10.1016/j.cmpb.2022.106864. [DOI] [PubMed] [Google Scholar]

Articles from Experimental and Computational Multiphase Flow are provided here courtesy of Nature Publishing Group

RESOURCES